dapagliflozin vs ertugliflozin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of dapagliflozin and ertugliflozin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Farxiga
Steglatro
Dapagliflozin (Farxiga) helps lower blood sugar in adults with type 2 diabetes. It also helps adults with heart failure or chronic kidney disease.
No summary available.
This medicine can help adults with chronic kidney disease by reducing the risk of kidney problems, heart problems, and needing to go to the hospital for heart failure. It can also help adults with heart failure by reducing the risk of heart problems and needing urgent care for heart failure. For adults with type 2 diabetes, it can help lower the risk of needing to go to the hospital for heart failure.
Information not available.
Dapagliflozin is a type of medicine called an SGLT2 inhibitor. It works in the kidneys to remove extra sugar from your body through your urine. This helps to lower your blood sugar levels.
Information not available.
- • Yeast infections of the vagina
- • Common cold
- • Urinary tract infections
- • Diarrhea
- • Nausea
- • Vomiting
- • Gas
- • Stomach discomfort
- Death 7,017
- Fatigue 2,250
- Nausea 2,218
- Dizziness 2,096
- Diarrhoea 2,074
- Nausea 86
- Urinary Tract Infection 62
- Vomiting 59
- Fungal Infection 58
- Diabetic Ketoacidosis 51
Dapagliflozin can cause a serious condition called diabetic ketoacidosis (DKA), especially if you have type 1 diabetes. Symptoms include nausea, vomiting, stomach pain, and trouble breathing. If you have these symptoms, stop taking this medicine and get medical help right away. This medicine can also cause serious infections in the area between your genitals and anus. Get medical help right away if you have pain, tenderness, redness, or swelling in this area, along with a fever or feeling unwell.
No specific warnings noted.
This medicine may harm your unborn baby, especially during the second and third trimesters. It is not recommended while breastfeeding.
No pregnancy information available.
Also Compare, Nearby Drugs
Compare dapagliflozin with
Compare ertugliflozin with
How to Read This dapagliflozin vs ertugliflozin Comparison
dapagliflozin is classified in the SGLT2 Inhibitor drug class, while ertugliflozin sits within the SGLT2 Inhibitor class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dapagliflozin has 15,655 submissions while ertugliflozin has 316. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dapagliflozin or ertugliflozin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.